This announcement follows the necessary regulatory review by the U.S. Federal Trade Commission and the U.S. Department of Justice. The addition of Ulthera’s energy device technology complements Merz’s current offerings and expands the specialty pharmaceutical company’s aesthetics portfolio.

This acquisition, valued at up to $600 million in upfront cash and milestone payments, is the largest in Merz’s history. It represents an important strategic milestone for the company as Merz continues to establish itself as a global leader in the area of aesthetics.

Founded in 2004, Ulthera provides non-surgical lifting and tightening treatments. Using therapeutic ultrasound technology, the Ulthera System is the first and only ultrasound platform device to receive a skin-lifting indication from the FDA.

Earlier this month, Ulthera announced that their proprietary Ulthera System has received FDA clearance to non-invasively treat the chest to improve lines and wrinkles of the décolleté, in addition to its clearance to lift skin on the brow, neck and under the chin.